Q2 2020 Nordic Nanovector ASA Earnings Call Transcript
Thanks Christine. Good morning, everyone, to our Q2 call from Nordic Nanovector. I'm Lars Nieba, the interim CEO of Nordic Nanovector. I have the Chairman, Jan Egberts with me on the phone; and in the room in Oslo, I have our CFO, Malene Brondberg. I would like to -- I would like to apologize Marco Renoldi. He had a death in the family, and therefore, cannot join us for the Q&A today.
I will now start with the slides. And we go to Slide #2. I would like to remind everybody on forward-looking statements.
And now to Slide #3. I would like to start with the Q2 highlights, which we had this year. We completed our strategic review and as you know, and which we already mentioned, we are focusing everything on PARADIGME and extended our cash runway into 2021. Our PARADIGME trial in third-line follicular lymphoma has enrolled 56 patients. The enrollment is still affected by COVID-19. I would like to point out that we are recruiting, which really speaks for Betalutin and its onetime injection where patients only need to be onetime at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
